The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
| Autor: | Andrey A. Zamyatnin, Jens Werner, Nikolay V. Mikhailovsky, Liubov I. Popova, Elena V. Abakushina, Alexandr V. Bazhin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_treatment
Immunology Cell Review NK cells NKG2D Cell therapy Cancer immunotherapy Drug Discovery cell-mediated immunity Medicine Cytotoxic T cell Pharmacology (medical) dendritic cells Pharmacology cancer immunotherapy business.industry adoptive cell therapy Immunotherapy Dendritic cell Infectious Diseases medicine.anatomical_structure tumor antigens Cancer research business cancer vaccines Ex vivo |
| Zdroj: | Vaccines, Vol 9, Iss 1363, p 1363 (2021) Vaccines |
| ISSN: | 2076-393X |
| Popis: | In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often used as vaccine carriers or antigen-presenting cells (APCs) to prime naive T cells ex vivo or in vivo. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are used as major tool effector cells for ACT. Despite the fact that NK cell immunotherapy is highly effective and promising against many cancer types, there are still some limitations, including insignificant infiltration, adverse conditions of the microenvironment, the immunosuppressive cellular populations, and the low cytotoxic activity in solid tumors. To overcome these difficulties, novel methods of NK cell isolation, expansion, and stimulation of cytotoxic activity should be designed. In this review, we discuss the basic characteristics of DC vaccines and NK cells as potential adoptive cell preparations in cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|